ERYTECH Pharma Stock Forecast, Price & News

Wall Street analysts have given ERYTECH Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ERYTECH Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ERYTECH Pharma saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 34,500 shares, a drop of 70.5% from the August 15th total of 116,900 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the shares of the company are short sold.
View ERYTECH Pharma's Short Interest.

ERYTECH Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, September 21st 2021.
View our earnings forecast for ERYTECH Pharma.

ERYTECH Pharma's stock was trading at $5.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ERYP stock has increased by 13.5% and is now trading at $5.95.
View which stocks have been most impacted by COVID-19.

Some companies that are related to ERYTECH Pharma include Molecular Partners (MOLN), Cellectis (CLLS), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHYF), Passage Bio (PASG), Gritstone bio (GRTS), MeiraGTx (MGTX), Talaris Therapeutics (TALS), Innate Pharma (IPHA), Aerie Pharmaceuticals (AERI), DBV Technologies (DBVT), Ambrx Biopharma (AMAM), Ikena Oncology (IKNA), CEL-SCI (CVM) and Poseida Therapeutics (PSTX).
View all of ERYP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD).

(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

ERYTECH Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (4.98%).

ERYP stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL.

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ERYP stock can currently be purchased for approximately $5.95.

ERYTECH Pharma has a market capitalization of $162.55 million and generates $4.25 million in revenue each year. The company earns $-83,730,000.00 in net income (profit) each year or ($4.55) on an earnings per share basis.

ERYTECH Pharma employs 206 workers across the globe.

The official website for ERYTECH Pharma is www.erytech.com.

ERYTECH Pharma is headquartered at 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008.

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438 or via email at [email protected].